Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

After a long-awaited approval for its CD19 targeting CAR-T liso-cel, Bristol Myers Squibb is gearing up for the looming review of another cell therapy in its pipeline, ide-cel. Taking not one but two CAR-Ts to market — and potentially more — means Bristol will have to step on the gas to get its manufacturing in order.

Looking to address that potential roadblock, Bristol will add a 244,000 square-foot cell therapy manufacturing facility at its Devens, MA site as it looks to grow its production capacity around liso-cel and, potentially, ide-cel in the coming weeks, the drugmaker said Tuesday.